You may have heard that BPC-157 has shown significant promise in the healing of an abundance of tissues including tendons, ligaments, muscles and bones.
But did you know that BPC-157 does some of its best work in the gut?
Surprisingly, it is stable in human stomach for more than 24 hours and can be easily delivered in capsule form without requiring injection. BPC 157 Is composed of 15 amino acids, is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice.
Experimentally it has been demonstrated to accelerate the healing of many different wounds, BPC, for reasons you're about to discover, stands for “Body Protecting Compound.” Your body already makes it in your own gastric juices in very small amounts, where it serves to protect and heal your gut. But if you can get the super-concentrated version and get it into your system, it has an extremely high level of biological healing activity just about anywhere you put it
BPC-157 is also known as a “stable gastric pentadecapeptide” primarily because it is stable in human gastric juice, can cause an anabolic healing effect in both the upper and lower GI tract, has an antiulcer effect, and produces a therapeutic effect on inflammatory bowel disease (IBD)—all again surprisingly free of side effects.
Oral BPC 157:
So, if you are looking to optimize your gut health or even your gut-brain axis, try BPC-157 today!
 Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptideBPC 157 in trials for inflammatory bowel disease (PL-10, PLD- 116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today 2007; 37: 768-77. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci 2008; 108: 7-17.Sever M, Klicek R, Radic B, et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci 2009; 54: 2070-83.
 Sikiric P, Seiwerth S, Brcic L, et al. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Curr Pharm 2010; 16: 1224-34.x
 BPC-157 is also known as a “stable gastric pentadecapeptide” primarily because it is stable in human gastric juice, can cause an anabolic healing effect in both the upper and lower GI tract, has an antiulcer effect, and produces a therapeutic effect on inflammatory bowel disease (IBD)—all again surprisingly free of side effects.
[i] Ilic S, Brcic I, Mester M, et al.Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. J Physiol Pharmacol. 2009; 60 Suppl 7: 107-14. , Ilic S, Drmic D, Franjic S, et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci, 2011; 88: 535-42. Sikiric P, Seiwerth S, Grabarevic Z, Balen I, Aralica G, Gjurasin M, Cysteamine-colon and cysteamine-duodenum lesions in rats.
Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone. J Physiol Paris. 2001; 95: 261-70. Prkacin I, Aralica G, Perovic D, et al. Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J Physiol Paris. 2001; 95: 295-301.